U.S. Stocks Mostly Higher, Nasdaq Up Over 1%
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 09 2026
0mins
Should l Buy HIMS?
Source: Benzinga
- Nasdaq Performance: The Nasdaq Composite rose by 1.15% to 23,295.01 on Monday, indicating strong performance in technology stocks and reflecting increased investor confidence in the tech sector.
- Dow Jones Decline: The Dow Jones Industrial Average fell slightly by 0.07% to 50,078.58, suggesting a relative weakness in traditional sectors, which may affect overall market sentiment.
- Sally Beauty Earnings Beat: Sally Beauty Holdings Inc (NYSE:SBH) reported an adjusted EPS of 48 cents for Q1, surpassing market expectations of 46 cents, with quarterly sales of $943.168 million exceeding the anticipated $940.150 million, demonstrating the company's resilience in a competitive market.
- Commodity Market Movements: On Monday, oil prices increased by 0.8% to $64.05, gold rose by 2.2% to $5,088.80, and silver surged by 7.9% to $82.94, reflecting heightened demand for safe-haven assets, which could influence future investment strategies.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HIMS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HIMS
Wall Street analysts forecast HIMS stock price to rise
12 Analyst Rating
3 Buy
6 Hold
3 Sell
Hold
Current: 22.160
Low
16.50
Averages
32.95
High
60.00
Current: 22.160
Low
16.50
Averages
32.95
High
60.00
About HIMS
Hims & Hers Health, Inc. provides a consumer-first platform, which helps customers to fulfill their health and wellness needs. Its platform includes access to a provider network, a clinically focused electronic medical record system, digital prescriptions, cloud pharmacy fulfillment, and personalization capabilities. Its digital platform enables access to treatments for a range of chronic conditions, including those related to sexual health, hair loss, dermatology, mental health, and weight loss. It connects patients to licensed healthcare professionals who can prescribe medications when appropriate and prescriptions are fulfilled online through licensed pharmacies on a subscription basis. It also offers access to a range of health and wellness products designed to meet individual needs, which can include curated prescription and non-prescription products. Through its mobile applications, consumers can access a range of educational programs, wellness content, and other services.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Hims & Hers Partners with Novo Nordisk for Weight-Loss Drugs
- Stock Surge: Hims & Hers Health closed at $22.15 on Monday, up 40.72%, primarily driven by the announcement of a collaboration with Novo Nordisk to sell GLP-1 weight-loss drugs, indicating strong market optimism for future growth.
- Volume Spike: The trading volume reached 168.1 million shares, about 557% above its three-month average of 25.6 million shares, reflecting heightened investor interest and increased market activity following the new partnership.
- Analyst Upgrades: Analysts at Needham and Citi raised their price targets for Hims & Hers to $30 and $24, respectively, signaling increased confidence in the company's future profitability, even as its stock remains down 62% from its 52-week high.
- Competitive Market Pressure: Despite the strong stock performance, the Motley Fool analyst team did not include Hims & Hers in their current list of top investment stocks, advising investors to carefully consider potential risks while pursuing high returns.
See More
BLKBRD Asset Management Fully Exits Hims & Hers Stake
- Stake Sale Overview: On February 17, 2026, BLKBRD Asset Management disclosed it sold all 318,666 shares of Hims & Hers Health, with an estimated transaction value of $18.07 million, reflecting a complete exit from its position during the fourth quarter.
- Impact on Asset Management: This sale reduced Hims & Hers' stake from 5% to 0%, indicating a significant loss of confidence from BLKBRD, which could negatively influence market perceptions of Hims & Hers.
- Stock Performance: As of February 16, 2026, Hims & Hers shares were priced at $16.30, down 72.46% over the past year, underperforming the S&P 500 by 84.25 percentage points, highlighting severe competitive challenges.
- Future Outlook: Although Hims & Hers recently announced a new partnership with Novo Nordisk that may provide a short-term stock rebound, ongoing market pressures and competitive challenges suggest that investors should carefully assess the company's long-term prospects.
See More
BLKBRD Asset Management Fully Exits Hims & Hers Stake
- Complete Exit: On February 17, 2026, BLKBRD Asset Management disclosed it fully exited its position in Hims & Hers Health by selling 318,666 shares, with an estimated trade value of $18.07 million, resulting in a 24.3% drop in the fund's quarterly average assets under management (AUM).
- Value Decline: The liquidation left Hims & Hers Health with a net position value of zero, previously accounting for 5.0% of the fund's AUM, indicating a complete loss of confidence in the stock by the fund.
- Market Reaction: Hims & Hers' stock has been in freefall since last June, plummeting from a historical high of $64 to around $15, primarily due to Novo Nordisk terminating its partnership and suing the company, which negatively impacted market expectations for its future.
- New Partnership Opportunity: Despite these challenges, Hims & Hers announced a new partnership with Novo Nordisk on March 10, 2026, to offer its weight-loss drugs Ozempic and Wegovy, leading to a 6% stock price increase and providing investors with a chance to reassess the company's prospects.
See More
Hims & Hers Shares Rise, BioNTech Crashes Amid Leadership Changes
- Hims & Hers Stock Surge: Shares of Hims & Hers rose 3% after Bank of America upgraded the stock from underperform to neutral, indicating market optimism about its potential to sell Novo's Ozempic and Wegovy drugs on its platform.
- BioNTech Shares Plummet: BioNTech's stock crashed over 20% following the announcement of its co-founders' departure to establish an independent company, alongside a reported fourth-quarter net loss of €305 million, highlighting deteriorating financial conditions.
- SolarEdge Stock Rises: Following Bank of America's upgrade to neutral, SolarEdge shares surged nearly 10%, reflecting increased market confidence in its improved margin trajectory, revenue stability, and liquidity.
- United Natural Foods Lowers Guidance: The grocery distributor reported second-quarter revenue of $7.95 billion, missing the $8.11 billion expected, and lowered its full-year revenue guidance to $31 billion to $31.4 billion, indicating ongoing market challenges.
See More
Hims & Hers Receives Upgrade Following Novo Nordisk Agreement, But Stock Gains May Remain Constrained.
- Stock Performance: Hims & Hers Health experienced its largest same-day stock jump on record following a new agreement with Novo Nordisk.
- Analyst Sentiment: Despite the stock surge, analysts remain cautious and are not quick to recommend investing in Hims & Hers Health.
See More
Hims & Hers Shares Raised Following Novo Nordisk Deal: Reasons to Hold Off on Buying.
- Stock Performance: Hims & Hers Health experienced its largest same-day stock jump on record following a new agreement with Novo Nordisk.
- Analyst Sentiment: Despite the stock surge, analysts remain cautious and are not quick to recommend investing in Hims & Hers Health.
See More
Hims & Hers Partners with Novo Nordisk for Weight-Loss Drugs
- Stock Surge: Hims & Hers Health closed at $22.15 on Monday, up 40.72%, primarily driven by the announcement of a collaboration with Novo Nordisk to sell GLP-1 weight-loss drugs, indicating strong market optimism for future growth.
- Volume Spike: The trading volume reached 168.1 million shares, about 557% above its three-month average of 25.6 million shares, reflecting heightened investor interest and increased market activity following the new partnership.
- Analyst Upgrades: Analysts at Needham and Citi raised their price targets for Hims & Hers to $30 and $24, respectively, signaling increased confidence in the company's future profitability, even as its stock remains down 62% from its 52-week high.
- Competitive Market Pressure: Despite the strong stock performance, the Motley Fool analyst team did not include Hims & Hers in their current list of top investment stocks, advising investors to carefully consider potential risks while pursuing high returns.
See More
BLKBRD Asset Management Fully Exits Hims & Hers Stake
- Stake Sale Overview: On February 17, 2026, BLKBRD Asset Management disclosed it sold all 318,666 shares of Hims & Hers Health, with an estimated transaction value of $18.07 million, reflecting a complete exit from its position during the fourth quarter.
- Impact on Asset Management: This sale reduced Hims & Hers' stake from 5% to 0%, indicating a significant loss of confidence from BLKBRD, which could negatively influence market perceptions of Hims & Hers.
- Stock Performance: As of February 16, 2026, Hims & Hers shares were priced at $16.30, down 72.46% over the past year, underperforming the S&P 500 by 84.25 percentage points, highlighting severe competitive challenges.
- Future Outlook: Although Hims & Hers recently announced a new partnership with Novo Nordisk that may provide a short-term stock rebound, ongoing market pressures and competitive challenges suggest that investors should carefully assess the company's long-term prospects.
See More
BLKBRD Asset Management Fully Exits Hims & Hers Stake
- Complete Exit: On February 17, 2026, BLKBRD Asset Management disclosed it fully exited its position in Hims & Hers Health by selling 318,666 shares, with an estimated trade value of $18.07 million, resulting in a 24.3% drop in the fund's quarterly average assets under management (AUM).
- Value Decline: The liquidation left Hims & Hers Health with a net position value of zero, previously accounting for 5.0% of the fund's AUM, indicating a complete loss of confidence in the stock by the fund.
- Market Reaction: Hims & Hers' stock has been in freefall since last June, plummeting from a historical high of $64 to around $15, primarily due to Novo Nordisk terminating its partnership and suing the company, which negatively impacted market expectations for its future.
- New Partnership Opportunity: Despite these challenges, Hims & Hers announced a new partnership with Novo Nordisk on March 10, 2026, to offer its weight-loss drugs Ozempic and Wegovy, leading to a 6% stock price increase and providing investors with a chance to reassess the company's prospects.
See More
Hims & Hers Shares Rise, BioNTech Crashes Amid Leadership Changes
- Hims & Hers Stock Surge: Shares of Hims & Hers rose 3% after Bank of America upgraded the stock from underperform to neutral, indicating market optimism about its potential to sell Novo's Ozempic and Wegovy drugs on its platform.
- BioNTech Shares Plummet: BioNTech's stock crashed over 20% following the announcement of its co-founders' departure to establish an independent company, alongside a reported fourth-quarter net loss of €305 million, highlighting deteriorating financial conditions.
- SolarEdge Stock Rises: Following Bank of America's upgrade to neutral, SolarEdge shares surged nearly 10%, reflecting increased market confidence in its improved margin trajectory, revenue stability, and liquidity.
- United Natural Foods Lowers Guidance: The grocery distributor reported second-quarter revenue of $7.95 billion, missing the $8.11 billion expected, and lowered its full-year revenue guidance to $31 billion to $31.4 billion, indicating ongoing market challenges.
See More
Hims & Hers Receives Upgrade Following Novo Nordisk Agreement, But Stock Gains May Remain Constrained.
- Stock Performance: Hims & Hers Health experienced its largest same-day stock jump on record following a new agreement with Novo Nordisk.
- Analyst Sentiment: Despite the stock surge, analysts remain cautious and are not quick to recommend investing in Hims & Hers Health.
See More
Hims & Hers Shares Raised Following Novo Nordisk Deal: Reasons to Hold Off on Buying.
- Stock Performance: Hims & Hers Health experienced its largest same-day stock jump on record following a new agreement with Novo Nordisk.
- Analyst Sentiment: Despite the stock surge, analysts remain cautious and are not quick to recommend investing in Hims & Hers Health.
See More
